South Korean contract development and manufacturing organization (CDMO) Samsung Biologics announced a rights offering to raise an expected aggregate amount of KRW 3 trillion (nearly $2.2 billion) to fund investments in the company’s long-term growth strategy.

“Building on our position as a global top-tier CDMO, this capital raise sets the stage for our next phase of growth,” Samsung Biologics CEO John Rim said in a statement. “We are confident that executing our three-dimensional growth strategy, including the acquisition of PolyPeptide Group and the expansion of Bio Campus II, will deepen our leadership and create lasting value for shareholders.” 

Samsung Biologics plans to “allocate approximately KRW 2.71 trillion of the offering proceeds toward the planned acquisition of PolyPeptide Group, with the remaining approximately KRW 290 billion designated for the expansion of Bio Campus II,” the company said in its announcement.

Last month, Samsung Biologics made an all-cash public tender offer to acquire Switzerland-headquartered CDMO PolyPeptide Group. The deal, worth $1.8 billion and to be completed by the end of 2026, is designed to target one of the fastest-growing biopharmaceutical segments — peptides — and boost Samsung’s multi-modality and global manufacturing capabilities.

The acquisition will expand Samsung’s capabilities beyond antibodies and antibody-drug conjugates (ADCs) to include peptide therapeutics, while advancing innovation across high-growth areas such as oncology and other emerging indications. The deal also grows the company’s global network to include PolyPeptide’s six cGMP manufacturing facilities in five countries — Belgium, France, India, Sweden, and the United States.

The transaction comes on the heels of Samsung Biologics acquiring a production facility in Rockville, Maryland from GSK — completed in March 2026 — and establishing the CDMO’s first U.S. manufacturing presence. The Rockville site includes two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity supporting both clinical and commercial biologics production across multiple scales. With the acquisition, the CDMO’s total global manufacturing capacity increases to 845,000 liters.

In South Korea, Samsung’s fully automated Plant 5 with digital systems went online last year — the company’s first facility at its Bio Campus II site in Songdo — adding 180,000 liters of capacity and bringing the CDMO’s total antibody production capacity to 784,000 liters. Bio Campus II, which will also include Plants 6, 7, and 8, is slated for completion by 2032 with total capacity of 720,000 liters.

“Following the completion of Plant 5 at the company’s Songdo Bio Campus II in 2025, Samsung Biologics has been evaluating bringing Plants 6 through 8 online sequentially, boosting its global manufacturing capacity to 1,385,000 liters by 2032,” the company said in Friday’s announcement about funding its next-phase expansion.

Last month, Samsung Biologics reported strong performance during the second quarter of 2026 — the result of “stable manufacturing operations” across Plants 1 through 4 at Bio Campus I in Songdo, despite union strike-related batch production disruptions in May.

Even with the Q2 batch production disruptions, the company said it is well positioned to achieve the upper end of its full-year revenue growth guidance (15% to 20% for 2026), driven in part by the ramp-up of Bio Campus II’s Plant 5 Process Performance Qualification (PPQ) batch production.